Patent ID: 6818650
Filing Date: 2004-11-16
Classification: A61P,C07D

Abstract:
A compound of the formula (I): wherein:A is a divalent linking group selected from the group consisting of: straight or branched chain C4-20 alkylene; straight or branched chain C4-20 alkenylene; straight or branched chain C4-20 alkynylene; and â€”Zâ€”Yâ€”Wâ€”Yâ€”Zâ€”; each Z is independently selected from the group consisting of: straight or branched chain C2-20 alkylene; straight or branched chain C4-20 alkenylene; and straight or branched chain C4-20 alkynylene; any of which may be optionally interrupted by â€”Oâ€”, â€”N(R5)â€”, or â€”S(O)2â€”; each Y is independently selected from the group consisting of: a bond; â€”N(R5)C(O)â€”; â€”C(O)N(R5)â€”; â€”N(R5)C(O)N(R5)â€”; â€”N(R5)S(O)2â€”; â€”S(O)2N(R5)â€”; â€”OC(O)Oâ€”; â€”OC(O)â€”; â€”C(O)Oâ€”; â€”N(R5)C(O)Oâ€”; and â€”OC(O)N(R5)â€”; W is selected from the group consisting of: straight or branched chain C2-20 alkylene; straight or branched chain C2-20 alkenylene; straight or branched chain C4-20 alkynylene; straight or branched chain perfluoro C2-20 alkylene; C1-4 alkylene-Oâ€”C1-4 alkylene; â€”C(O)â€”; â€”S(O)2â€”; â€”OC(O)Oâ€”; â€”N(R5)C(O)N(R5)â€”; 1,5-naphthylene; 2,6-pyridinylene; 1,2-cyclohexylene; 1,3-cyclohexylene; 1,4-cyclohexylene; trans-1,4-cyclohexylene; andtrans-5-norbornen-2,3-diyl; wherein n is 0-4; each R is independently selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, and halogen; and Q is selected from the group consisting of a bond, â€”CH2â€”, and â€”Oâ€”; R2 is selected from the group consisting of: -hydrogen; -alkyl; -alkenyl; -aryl; -substituted aryl; -heteroaryl; -substituted heteroaryl; -alkyl-X-alkyl; -alkyl-X-aryl; -alkyl-X-alkenyl; and -alkyl or alkenyl substituted by one or more substituents selected from the group consisting of: â€”OH; -halogen; â€”N(R6)2; â€”C(O)â€”N(R6)2; â€”C(S)â€”N(R6)2; â€”S(O)2â€”N(R6)2; â€”N(R6)â€”C(O)â€”C1-10 alkyl; â€”N(R6)â€”C(S)â€”C1-10 alkyl; â€”N(R6)â€”S(O)2â€”C1-10 alkyl; â€”C(O)â€”C1-10 alkyl; â€”C(O)â€”Oâ€”C1-10 alkyl; â€”N3; -aryl; -substituted aryl; -heteroaryl; -substituted heteroaryl; -heterocyclyl; -substituted heterocyclyl; â€”C(O)-aryl; â€”C(O)-(substituted aryl); â€”C(O)-heteroaryl; and â€”C(O)-(substituted heteroaryl); R3 and R4 are each independently selected from the group consisting of: -hydrogen; -halogen; -alkyl; -alkenyl; -X-alkyl; and â€”N(R6)2; or when taken together, R3 and R4 form a fused aryl or heteroaryl ring that is unsubstituted or substituted by one or more substituents selected from the group consisting of: -halogen; -alkyl; -alkenyl; -X-alkyl; and â€”N(R6)2; or when taken together, R3 and R4 form a fused 5 to 7 membered saturated ring, containing 0 to 2 heteroatoms and unsubstituted or substituted by one or more substituents selected from the group consisting of: -halogen; -alkyl; -alkenyl; -X-alkyl; and â€”N(R6)2; each R5 is independently selected from the group consisting of: hydrogen; C1-6 alkyl; C3-7 cycloalkyl; and benzyl; or when Y is â€”N(R5)C(O)â€”, â€”C(O)N(R5)â€”, â€”N(R5)C(O)N(R5)â€”, â€”N(R5)S(O)2â€”, â€”S(O2)N(R5)â€”, â€”N(R5)C(O)Oâ€”, or â€”OC(O)N(R5)â€” and the nitrogen of the N(R5) group is bonded to Z, then R5 can join with Z to form a ring having the structure each R6 is independently hydrogen or C1-10 alkyl; R7 is C3-8 alkylene; and X is â€”Oâ€” or â€”Sâ€”; with the proviso that if W is â€”C(O)â€”, â€”S(O)2â€”, â€”OC(O)Oâ€”, or â€”N(R5)C(O)N(R5)â€” then each Y is a bond;or a pharmaceutically acceptable salt thereof.